WallStSmart

biote Corp (BTMD)vsHCA Healthcare, Inc. (HCA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 40497% more annual revenue ($76.39B vs $188.16M). HCA leads profitability with a 8.9% profit margin vs 8.3%. BTMD trades at a lower P/E of 5.1x. HCA earns a higher WallStSmart Score of 63/100 (C+).

BTMD

Hold

35

out of 100

Grade: F

Growth: 3.3Profit: 6.5Value: 8.3Quality: 7.0
Piotroski: 4/9Altman Z: 2.77

HCA

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTMDUndervalued (+47.8%)

Margin of Safety

+47.8%

Fair Value

$4.06

Current Price

$2.10

$1.96 discount

UndervaluedFair: $4.06Overvalued
HCASignificantly Overvalued (-85.5%)

Margin of Safety

-85.5%

Fair Value

$286.48

Current Price

$372.13

$85.65 premium

UndervaluedFair: $286.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTMD2 strengths · Avg: 10.0/10
P/E RatioValuation
5.1x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-1.9310/10

Conservative balance sheet, low leverage

HCA4 strengths · Avg: 9.3/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.9110/10

Conservative balance sheet, low leverage

Market CapQuality
$86.51B9/10

Large-cap with strong market position

P/E RatioValuation
13.4x8/10

Attractively priced relative to earnings

Areas to Watch

BTMD4 concerns · Avg: 2.5/10
Market CapQuality
$77.86M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

EPS GrowthGrowth
-83.8%2/10

Earnings declined 83.8%

HCA2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BTMD

The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bear Case : BTMD

The primary concerns for BTMD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

BTMD carries more volatility with a beta of 1.66 — expect wider price swings.

HCA is growing revenue faster at 4.3% — sustainability is the question.

HCA generates stronger free cash flow (895M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HCA scores higher overall (63/100 vs 35/100). BTMD offers better value entry with a 47.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

biote Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

biote corp. The company is headquartered in Irvine, Texas.

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?